<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014360</url>
  </required_header>
  <id_info>
    <org_study_id>CR109012</org_study_id>
    <secondary_id>2021-001068-16</secondary_id>
    <secondary_id>64251330COR1001</secondary_id>
    <nct_id>NCT05014360</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis</brief_title>
  <official_title>A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of JNJ-64251330 in participants with&#xD;
      Familial Adenomatous Polyposis (FAP) on colorectal polyp burden (sum of the polyp diameters).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial adenomatous polyposis (FAP) is the most common polyposis syndrome. It is an&#xD;
      autosomal dominant inherited disorder characterized by the early onset of hundreds to&#xD;
      thousands of adenomatous polyps throughout the colon. JNJ-64251330 (lorpucitinib) is an oral,&#xD;
      small molecule, potent pan-janus kinase (JAK) inhibitor that blocks phosphorylation of Signal&#xD;
      Transducer and Activator of Transcription (STAT) proteins. pSTAT induces transcription of&#xD;
      multiple genes involved in the progression of inflammatory disease. JNJ-64251330 has chemical&#xD;
      properties that limits the amount of drug in the blood while delivering the drug to the&#xD;
      tissues of the gut. Local inhibition of JAK in the gut may present a promising method to&#xD;
      treat inflammatory diseases of the intestinal tract, such as FAP. The study consists of 3&#xD;
      phases: screening phase (30 days) a treatment phase (24 weeks), and follow-up visit (up to 30&#xD;
      days after last dose of study drug). The total duration of the study will be up to 32 weeks.&#xD;
      Study evaluations will include efficacy via endoscopies, safety (monitoring of adverse events&#xD;
      (AE), serious adverse events (SAEs), events of infections including tuberculosis (TB),&#xD;
      clinical laboratory blood tests (complete blood count and serum chemistries), vital signs,&#xD;
      and concomitant medication review), pharmacokinetics, pharmacodynamic and biomarkers&#xD;
      evaluations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 12, 2021</start_date>
  <completion_date type="Anticipated">June 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change from Baseline in Colorectal Polyp Burden for all Polyps at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change from baseline in colorectal polyp burden for all polyps (the sum of the polyp diameters) at Week 24 will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change from Baseline in Colorectal Polyp Burden for Polyps &gt;=2 mm at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change from baseline in colorectal polyp burden (sum of the polyp diameters) for polyps greater than or equal to (&gt;=) 2 millimeters (mm) at Week 24 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Number of Colon Polyps</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change in number of colon polyps will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Number of Rectal Polyps</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change in number of rectal polyps will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Number of J-pouch Polyps</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change in number of J-pouch polyps (for participants with an ileal pouch-anal anastomosis [IPAA]) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Number of Duodenal Polyps</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change in number of duodenal polyps will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Colon Polyp Burden for all Polyps, Polyps &gt;=2 mm and Polyps &gt;=5 mm</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change in colon polyp burden for all polyps, polyps &gt;=2 mm and polyps &gt;=5 mm will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Rectal Polyp Burden for all Polyps, Polyps &gt;=2 mm and Polyps &gt;=5 mm</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change in rectal polyp burden for all polyps, polyps &gt;=2 mm and polyps &gt;=5 mm will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in J-Pouch Polyp Burden for all Polyps, Polyps &gt;=2 mm and Polyps &gt;=5 mm</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change in J-Pouch polyp (for participants with an IPAA) burden for all polyps, polyps &gt;=2 mm and polyps &gt;=5 mm will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Duodenal Polyp Burden for all Polyps, Polyps &gt;=2 mm and Polyps &gt;=5 mm</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Percentage change in duodenal polyp burden for all polyps, polyps &gt;=2 mm and polyps &gt;=5 mm will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Polyposis Stage (with and Without Colon)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change in InSiGHT stage will be reported. Various stages are defined as: a) With Colon: Stage 0: 0-10 polyps,all less than [&lt;]5mm); Stage 1: 20-200 polyps,most &lt;5 mm, none, &gt;1 centimeters[cm]; Stage 2: 200-500 polyps,&lt;10 that are &gt;1 cm; Stage 3: 500-1000 polyps or any number if there are 10-50 that are &gt;1 cm and amenable to complete polypectomy; Stage 4: &gt;1000 polyps and/or any polyps grown to confluence and not amenable to simple polypectomy, any invasive cancer; b) Without Colon: Stage 0: 0 -10 polyps, all &lt;5 mm; Stage 1: 10-25 polyps most &lt;5 mm, none &gt;1 cm; Stage 2: 10-25 polyps, any &gt;1 amenable to complete removal; Stage 3: &gt;25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of high-grade dysplasia (HGD), even if completely excised; Stage 4: &gt;25 polyps not amenable complete removal, or any incompletely excised sessile polyp showing HGD; any invasive cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spigelman Stage Score</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change in Spigelman stage score will be reported. Spigelman classification system measures risk of developing duodenal cancer in familial adenomatous polyposis (FAP). It has been classified in following stages- Stage 0 (0 points); Stage 1 (1-4 points); Stage 2 (5-6 points); Stage 3 (7-8 points); and Stage 4 (9-12 points). The total score ranges from 0 to 12. The higher the score, the more severe or advanced the FAP disease in the duodenum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with AEs by Severity</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Number of participants with AEs by severity will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of JNJ-64251330 Over Time</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Plasma samples will be analyzed to determine plasma concentrations of JNJ-64251330 using a validated specific, and sensitive liquid chromatography coupled to tandem mass spectrometry detection (LC-MS/MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue Concentration of JNJ-64251330 Over Time</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Tissue biopsy samples will be analyzed to determine tissue concentrations of JNJ-64251330 using a validated specific, and sensitive LC-MS/MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of JAK/STAT Pathway Signaling Effector Proteins including pSTAT-3 Relative to Baseline Levels in Colorectal Polyps</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Levels of Pan-janus kinase (JAK)/ signal transducer and activator of transcription (STAT) pathway signaling effector proteins including phosphorylated (p) STAT-3 relative to baseline levels in colorectal polyps will be reported. Polyp and tissue samples will be collected to monitor for changes to the JAK-STAT pathway.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Adenomatous Polyposis Coli</condition>
  <arm_group>
    <arm_group_label>JNJ-64251330</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64251330</intervention_name>
    <description>JNJ-64251330 tablets will be administered orally.</description>
    <arm_group_label>JNJ-64251330</arm_group_label>
    <other_name>Lorpucitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genetic diagnosis of classical familial adenomatous polyposis (FAP) (adenomatous&#xD;
             polyposis coli [APC] germline mutation or obligate carrier) with disease involvement&#xD;
             of the colorectum&#xD;
&#xD;
          -  At least 6 polyps greater than or equal to (&gt;=) 2 millimeters (mm) in diameter in the&#xD;
             rectum or colon&#xD;
&#xD;
          -  A female participant of childbearing potential must have a negative highly sensitive&#xD;
             pregnancy test at screening and within 72 hours prior to the first dose of study drug&#xD;
             and must agree to further pregnancy tests during the study&#xD;
&#xD;
          -  A male participant must agree not to donate sperm for the purpose of reproduction&#xD;
             during the study and for a minimum of 90 days after receiving the last dose of study&#xD;
             drug&#xD;
&#xD;
          -  Must sign an informed consent form (ICF) indicating he or she understands the purpose&#xD;
             of the study and procedures required for the study and is willing to participate in&#xD;
             the study. Consent is to be obtained prior to the initiation of any study-related&#xD;
             tests or procedures that are not part of standard of care for the participant's&#xD;
             disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of non-steroidal anti-inflammatory drugs (example, aspirin, ibuprofen) exceeding 5&#xD;
             days per month or exceeding the nonprescription dose, unless the participant completes&#xD;
             a 4-week washout period prior to the first dose of study drug&#xD;
&#xD;
          -  Treatment with other FAP-directed drug therapy (including sulindac or celecoxib),&#xD;
             unless completes a 4-week washout period prior to the first dose of study drug&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  History of severe, progressive, or uncontrolled renal, genitourinary, hepatic,&#xD;
             hematologic, endocrine, cardiac, vascular, pulmonary, rheumatologic, neurologic,&#xD;
             psychiatric, or metabolic disturbances, or signs and symptoms thereof&#xD;
&#xD;
          -  A history of, or ongoing, chronic or recurrent infectious disease including latent or&#xD;
             active tuberculosis (TB)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wexner Medical Center at the Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM Hopital Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Universiteit van Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pan American Center for Oncology Trials LLC</name>
      <address>
        <city>RÃ­o Piedras</city>
        <zip>00 935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinic I Provincial de Barcelona</name>
      <address>
        <city>Madrid</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Univ. de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

